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P ermanent brachytherapy is a standard treatment in patients with low- or intermediate-risk prostate 
cancer [1 , 2].  It is often performed in combination with 
neoadjuvant hormone therapy (NHT) [3].  The European 
Association of Urology guidelines state that there is no 
benefit of providing NHT before brachytherapy in terms 
of oncologic outcomes such as biochemical recurrence- 
free survival [4].  Similarly,  we have reported that NHT 
did not improve oncologic outcomes in patients with 
localized prostate cancer and was only successful in 
reducing the prostate volume (≥ 35 mL) [5].
Testosterone levels usually recover from a castrated 
level to a normal level after the discontinuation of 
androgen deprivation therapy (ADT) [6].  However,  
some patients treated with NHT before brachytherapy 
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Optimal neoadjuvant hormone therapy (NHT) for reducing prostate cancer (PC) patients’ prostate volume 
pre-brachytherapy is controversial.  We evaluated the differential impact of neoadjuvant gonadotropin-releas-
ing hormone (GnRH) antagonist versus agonist on post-brachytherapy testosterone recovery in 112 patients 
treated pre-brachytherapy with NHT (GnRH antagonist,  n = 32; GnRH agonists,  n = 80) (Jan. 2007-June 2019).  
We assessed the effects of patient characteristics and a GnRH analogue on testosterone recovery with logistic 
regression and a propensity score analysis (PSA).  There was no significant difference in the rate of testosterone 
recovery to normal levels (> 300 ng/dL) between the GnRH antagonist and agonists (p= 0.07).  The GnRH ago-
nists induced a significantly more rapid testosterone recovery rate at 3 months post-brachytherapy versus the 
GnRH antagonist (p< 0.0001); there was no difference in testosterone recovery at 12 months between the GnRH 
antagonist/agonists (p= 0.8).  In the multivariate analysis,  no factor was associated with testosterone recovery.  
In the PSA,  older age and higher body mass index (BMI) were significantly associated with longer testosterone 
recovery.  Post-brachytherapy testosterone recovery was quicker with the neoadjuvant GnRH agonists than the 
antagonist,  and the testosterone recovery rate was significantly associated with older age and higher BMI.  
Long-term follow-ups are needed to determine any differential effects of GnRH analogues on the quality of life 
of brachytherapy-treated PC patients.
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do not experience persistent testosterone recovery.  Low 
testosterone levels can result in increased risks of car-
diovascular diseases (CVDs),  diabetes,  and osteoporo-
sis [7].  Some studies reported that testosterone therapy 
did not increase the risks of biochemical recurrence,  
cancer-specific mortality or overall mortality after sur-
gery or radiation in patients with localized prostate 
cancer [8 , 9].  Tsumura et al.  investigated the factors 
predictive of testosterone recovery in patients treated 
with brachytherapy,  and they observed that the dura-
tion of hormone therapy was significantly associated 
with testosterone recovery [10].  On the other hand,  
Kato et al.  reported that testosterone recovery after NHT 
was associated with body mass index (BMI) and hyper-
tension [11].  A recent meta-analysis demonstrated that 
treatment with a gonadotropin-releasing hormone 
(GnRH) antagonist was associated with lower rates of 
musculoskeletal and cardiovascular events such as 
angina pectoris and myocardial ischemia,  compared to 
GnRH agonists [12 , 13].
We hypothesized that a GnRH antagonist might 
induce earlier testosterone recovery compared to GnRH 
agonists,  and we conducted the present study to inves-
tigate the association between the types of GnRH ana-
logue and testosterone recovery.
Patients and Methods
Patient population and management. We ana-
lyzed the cases of 132 patients treated with NHT (32 
with a GnRH antagonist and 80 with GnRH agonists) 
before permanent iodine-125 seed brachytherapy at 
Okayama University Hospital during the period from 
January 2007 to June 2019.  The oral anti-androgen 
(bicalutamide) was administered according to the treat-
ing physician’s discretion.  Two patients (6%) with a 
GnRH antagonist and 7 patients (9%) with a GnRH 
agonist were administered bicalutamide,  respectively.  
We excluded patients treated with other oral anti- 
androgens and those with a follow-up duration of < 1 
year.  The risk classification of the patients was per-
formed according to the U.S.  National Comprehensive 
Cancer Network guidelines.
Study protocol. The brachytherapy technique used 
at our institution has been described [5]; briefly,  when 
the prostate volume is observed by transrectal ultraso-
nography to be ≥ 35 mL or an adequate dose–volume 
histogram cannot be determined due to pubic arch 
interference,  NHT is administered for 3 months as a 
general rule.  If the prostate volume is not sufficiently 
reduced by the NHT,  an additional 3-month course of 
the NHT is administered [5].  In the present patient 
series,  the GnRH antagonist used was degarelix 
(240 mg initial dose,  80 mg subsequent doses),  and the 
GnRH agonists used were leuprolide (3.75 mg or 
11.25 mg) and goserelin (3.6 mg or 10.8 mg).  The NHT 
(GnRH antagonist or agonists) was administered at the 
discretion of the treating physician without any specific 
protocol.
We assessed patient age,  BMI,  histories of hyper-
tension and diabetes mellitus,  initial prostate-specific 
antigen value,  pathological stage,  Gleason grade group,  
and the duration of hormone therapy before the 
patient’s brachytherapy.  Patients were followed rou-
tinely for the measurement of the levels of prostate- 
specific antigen and serum testosterone every 3 months 
during the first year,  every 6 months during the subse-
quent 4 years,  and annually thereafter.  A normal serum 
testosterone level (testosterone recovery) was defined as 
≥ 300 ng/dL,  according to the American Urological 
Association guidelines [14].
This study was conducted in accordance with the 
Declaration of Helsinki and was approved by the 
Okayama University Ethics Committee Institutional 
Review Board (approval no. 2011-015).
Statistical analyses. The Mann–Whitney U-test 
and Fisher’s exact test were used to assess the statistical 
significance of differences in medians and proportions 
between groups,  respectively.  The follow-up duration 
was calculated from the date of the patient’s 
brachytherapy.  The Kaplan–Meier estimate was used to 
evaluate the cumulative rate of testosterone recovery.  
Gray’s test was used to evaluate differences in testoster-
one recovery according to the types of GnRH analogue.  
A logistic regression model including age,  BMI,  histo-
ries of hypertension and diabetes mellitus,  and combi-
nation of anti-androgen treatments was used to calcu-
late propensity scores.  A one-to-one pair matching 
without replacement was performed by the near-
est-neighbor matching method with a 0.2 caliper.  We 
performed a univariate logistic regression analysis to 
identify the factors predictive of testosterone recovery.  
Variables with p < 0.05 in the univariate analysis,  as well 
as the GnRH analogue type (antagonist vs. agonist),  
were evaluated in the multivariate analysis.  Statistical 
significance was set at p < 0.05,  and all tests were two-
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sided.  All statistical analyses were performed using EZR 
ver. 1.36 (Saitama Medical Center,  Jichi Medical 
University,  Saitama,  Japan),  a graphical user interface 
for R [15].
Results
There was no significant difference in age,  BMI,  ini-
tial PSA level,  history of hypertension or diabetes mel-
litus,  rates of combination with an anti-androgen,  or 
the duration of ADT between the patients who received 
a GnRH antagonist and those who received GnRH ago-
nists.  The group of patients treated with a GnRH antag-
onist showed significantly more advanced pathological 
T stages (p < 0.0001) and included significantly more 
intermediate-risk patients (p = 0.04) compared to the 
patients in the agonist group (Table 1).
Prostate volume reduction. Figure 1 illustrates 
the reductions in prostate volume after NHT in the 
GnRH antagonist and agonists groups.  The prostate 
volume before NHT was significantly greater in the 
patients treated with a GnRH antagonist compared to 
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Table 1　 Patient baseline demographic and pathological characteristics according to gonadotropin-releasing hormone analogue type in 
full sample and propensity score matched cohort.
Full sample Propensity score match
Antagonist Agonist P-value Antagonist Agonist P-value
Number of patients 32 80 32 32
Age (years),  median (IQR) 69 (65-72) 68 (64-70) 0.3 69 (65-78) 69 (66-70) 0.6
BMI (kg/m2),  median (IQR) 24 (22-26) 24 (21-26) 0.2 24 (22-26) 25 (23-26) 0.4
Initial PSA level (ng/mL),  median (IQR) 7.7 (5.3-12.9) 7.3 (5.4-9.6) 0.2 7.7 (5.3-12.9) 7.6 (5.7-11.1) 0.6
Pathological T stage <0.0001 <0.0001
　T1c,  n (%) 11 (34) 60 (75) 11 (34) 27 (84)
　T2a,  n (%) 17 (53) 14 (18) 17 (53) 3 (9)
　T2b,  n (%) 0 (0) 4 (5) 0 (0) 2 (6)
　T2c,  n (%) 4 (13) 2 (2) 4 (13) 0 (0)
Gleason grade group 0.2 0.2
　1,  n (%) 18 (56) 58 (73) 18 (56) 24 (75)
　2,  n (%) 14 (44) 21 (26) 14 (44) 8 (25)
　3,  n (%) 0 (0) 1 (1)
NCCN risk group 0.04 0.1
　Low,  n (%) 9 (28) 41 (51) 9 (28) 16 (50)
　Intermediate,  n (%) 23 (72) 39 (49) 23 (72) 16 (50)
Hypertension,  n (%) 15 (47) 27 (34) 0.2 15 (47) 14 (44) 1
Diabetes mellitus,  n (%) 4 (13) 11 (14) 1 4 (13) 2 (6) 0.7
Combination with anti-androgen,  n (%) 2 (6) 7 (9) 1 2 (6) 4 (13) 0.7
Duration of ADT,  median (IQR) 3 (3-3) 3 (3-3) 0.1 3 (3-4) 3 (3-3) 0.2
　<3 months,  n (%) 25 (78) 66 (83) 25 (78) 23 (72)
　>3 months,  n (%) 7 (22) 14 (17) 7 (22) 9 (28)
ADT,  androgen deprivation therapy; BMI,  body mass index; NCCN,  national comprehensive cancer network; PSA,  prostate specific 
antigen.
those treated with GnRH agonists (p = 0.008),  but there 
was no significant difference between the groups after 
NHT (p = 0.4).  There was no significant difference in 
prostate volume reduction between the patients treated 
with the two GnRH agonists (leuprolide vs. goserelin) 
(data not shown).
Testosterone recovery. The patients’ testosterone 
recovery rates are shown in Table 2.  The rates of recov-
ery to normal testosterone levels in the GnRH antago-
nist versus agonist groups were 9% (3/32 patients) vs. 
55% (40/73) at 3 months,  44% (14/32) vs. 64% (50/78) 
at 6 months,  63% (20/32) vs. 73% (58/80) at 9 months,  
and 72% (23/32) vs. 75% (60/80) at 12 months after 
brachytherapy,  respectively.  Interestingly,  the GnRH 
agonists induced significantly more rapid testosterone 
recovery rate at 3 months after brachytherapy compared 
to the GnRH antagonist (p < 0.0001),  but there was no 
significant difference in testosterone recovery at 
12 months (p = 0.8) after brachytherapy between the 
GnRH antagonist and agonist groups.  In the multivari-
ate analysis,  no factor was associated with testosterone 
recovery (Table 3).  There was no significant difference 
in the testosterone recovery rates between the GnRH 
agonists (leuprolide vs. goserelin) (data not shown).
Propensity score analysis. The testosterone level 
is affected by age,  BMI,  history of hypertension,  his-
tory of diabetes mellitus,  and anti-androgen therapy 
[16].  We thus performed propensity score matching of 
the two groups using these covariates.  The patient char-
acteristics of the propensity score-matched cohorts are 
given in Table 1.  In the Kaplan–Meier estimate,  there 
was no significant difference in testosterone recovery 
rates between the GnRH antagonist and agonist groups 
(p = 0.07) (Fig. 2),  with a significant difference in the 
testosterone recovery rate between the two groups seen 
at 3 months after brachytherapy (p < 0.0001) (Table 2).  
In the multivariate analysis performed after propensity 
score matching,  older age and higher BMI were signifi-
cantly associated with longer testosterone recovery 
(Table 3).
Discussion
With the increasing interest in focal therapy for 
prostate cancer,  brachytherapy was introduced in Japan 
in 2003,  and more than 43,000 patients have undergone 
brachytherapy in Japan since then [1].  The impact of 
NHT on prostate cancer prior to brachytherapy is still 
controversial.  The NHT agent (e.g.,  GnRH antagonists 
and agonists) and duration should be considered in the 
decision whether to perform NHT.  At our institution,  
when the prostate volume is ≥ 35 mL or an adequate 
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Table 2　 Testosterone recovery rates at different time points after brachytherapy according to type of gonadotropin-releasing hormone 
analogue in full sample and propensity score matched cohort
Full sample Propensity score match
Antagonist Agonist P-value Antagonist Agonist P-value
Number of patients 32 80 32 32
Testosterone recovery rates
　3 month,  n (%) 3/32 (9) 40/73 (55) <0.0001 3/32 (9) 17/28 (61) <0.0001
　6 month,  n (%) 14/32 (44) 50/78 (64) 0.058 14/32 (44) 22/31 (71) 0.042
　9 month,  n (%) 20/32 (63) 58/80 (73) 0.4 20/32 (63) 23/32 (72) 0.6














Fig. 1　 Prostate volume reduction after treatment with a gonado-
tropin-releasing hormone (GnRH) antagonist or agonists.  Pre,  pre-
treatment of neoadjuvant hormone therapy (NHT); Post,  post-treat-
ment of NHT.
dose–volume histogram cannot be determined due to 
pubic arch interference,  a 3-month NHT regimen is 
generally administered.  Our present study’s analyses 
revealed no significant difference in prostate volume 
reduction between the patients treated with a GnRH 
antagonist and those treated with GnRH agonists.  This 
finding is consistent with that of Axcrona et al.,  who 
performed a randomized controlled trial in 179 patients 
treated with NHT for 12 weeks prior to definitive treat-
ment [17].  They also reported that degarelix was 
non-inferior to goserelin in terms of prostate volume 
reduction.
The use of ADT can cause adverse events such as 
fatigue,  decreased sexual function,  hot flushes,  and 
most importantly CVDs,  which is due mainly to testos-
terone suppression [18 , 19].  Some studies demon-
strated that lower testosterone levels were correlated 
with the increased risk of CVDs and mortality [20 , 21].  
Androgens induce vascular-protective effects such as an 
attenuation of vascular inflammation and atherosclero-
sis as well as the promotion of the restoration of the 
endothelial layer [22 , 23].  A prolonged decrease in the 
testosterone level after NHT may potentially have not 
only physical but also psychological effects [24].  
Therefore,  NHT regimens that induce a rapid recovery 
of a patient’s testosterone level should be recommended 
to improve the quality of life (QOL) of patients with 
localized prostate cancer.  In the present series,  the rate 
of testosterone recovery to a normal level was 72% in 
the GnRH antagonist group and 75% in the GnRH ago-
nist group (p = 0.8) at 12 months after brachytherapy.  
These results are comparable with those of previous 
studies [11 , 25 , 26].
The risk of hypogonadism is increased by older age,  
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Table 3　 Logistic regression analyses of predictive factors associated with testosterone recovery at 12 months after brachytherapy 
before and after propensity score matching
Univariate
odds ratio (95%CI) P-value
Multivariate





Age 0.87 (0.783-0.967) 0.01 0.885 (0.783-1.00) 0.051 0.794 (0.639-0.988) 0.04
BMI 0.842 (0.72-0.983) 0.03 0.857 (0.722-1.02) 0.077 0.736 (0.55-0.986) 0.04
Initial PSA level 0.985 (0.869-1.12) 0.8
T stage 0.861 (0.497-1.49) 0.6
Gleason grade 0.844 (0.332-2.15) 0.7
NCCN risk group 1.31 (0.514-3.33) 0.6
GnRH antagonist vs agonist 1.57 (0.586-4.21) 0.4 1.26 (0.437-3.63) 0.7 3.68 (0.738-19.4) 0.1
Hypertension 0.417 (0.162-1.07) 0.07 0.603 (0.218-1.67) 0.3 0.341 (0.133-1.74) 0.2
Diabetes 0.296 (0.093-0.949) 0.04 0.73 (0.181-2.94) 0.3 1.13 (0.067-9.68) 0.9
Combination with anti-androgen 2.05 (0.243-17.3) 0.5
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Fig. 2　 Cumulative rate of recovery to normal testosterone levels 
after treatment with a GnRH antagonist or agonists.
obesity,  history of hypertension,  and diabetes [16].  
Kato et al.  investigated testosterone recovery according 
to the type of GnRH analogue used,  and they reported 
an earlier recovery to normal testosterone levels with a 
GnRH antagonist compared with GnRH agonists [11].  
Some studies suggested that GnRH antagonists can pro-
vide an alternative treatment to intermittent ADT 
[27 , 28]; those authors demonstrated that for intermit-
tent ADT,  it is necessary to maintain low testosterone 
levels during ADT and to allow an early recovery of 
testosterone levels during the off-treatment period.  
Contrary to our hypothesis,  our present findings 
demonstrated that the GnRH agonists induced a signifi-
cantly more rapid testosterone recovery compared to the 
GnRH antagonist at 3 months after brachytherapy 
(p < 0.0001).
A GnRH agonist functions to overstimulate GnRH 
receptors,  causing receptor desensitization and,  conse-
quently,  a reduction of the levels of luteinizing hor-
mone (LH) and follicle-stimulating hormone (FSH).  
Testosterone suppression is achieved after an initial LH 
surge,  which not only delays the reduction to a cas-
trated testosterone level but also stimulates an overpro-
duction of testosterone [29].  Klotz et al.  demonstrated 
that GnRH antagonists rapidly suppress LH and FSH 
levels and maintain their suppression,  whereas GnRH 
agonists do not suppress the FSH level to the same 
extent as GnRH antagonists [30].  The maintained FSH 
function might lead to a more rapid testosterone recov-
ery after a discontinuation of the agonist.
The propensity score analysis conducted herein 
revealed that the prostate cancer patients’ testosterone 
recovery was significantly associated with age and BMI,  
but not with the types of GnRH analogue; these results 
are somewhat inconsistent with previous research 
[11 , 31].  The median duration of NHT was 3 months in 
the present study versus 6 months in tis earlier research.  
In addition,  we administered bicalutamide to only nine 
patients,  whereas in the previous research,  all of 
patients were administered bicalutamide.  The differ-
ences in the duration of NHT and the administration 
rate of the anti-androgen might have led to the discrep-
ancy in results between studies.  A randomized con-
trolled trial is underway to assess the benefit and potency 
of a GnRH antagonist compared with GnRH agonists as 
NHT before brachytherapy (UMIN000015519) [32].  
We are awaiting the results of the prospective study.
There are some study limitations to address,  includ-
ing the relatively small sample size and retrospective 
design.  We thus performed the propensity score 
matching to reduce the potential bias introduced by 
these limitations.  Another limitation was that we could 
not assess the influence of the patients’ pre-treatment 
testosterone level on testosterone recovery,  as the 
pre-treatment testosterone levels were not available.  It 
is possible that the more advanced stages (higher T 
stage and intermediate risk group) in the group of 
patients treated with the GnRH antagonist was a factor 
in the delayed testosterone recovery.  In addition,  the 
duration of NHT was prolonged in some cases if a suffi-
cient reduction in prostate volume was not achieved;  
thus,  the NHT duration was not equal among the study 
patients.  Finally,  we did not evaluate the detrimental 
physiological effects of NHT (e.g.,  risk of CVDs) or 
psychological effects of NHT (e.g.,  on QOL).  Long-
term follow-up is needed to determine whether differ-
ences in the duration of testosterone recovery by the 
types of GnRH analogue affect the risk of CVDs.
In conclusion,  between the GnRH antagonist and 
agonists evaluated here,  the GnRH agonists induced a 
more rapid recovery of the testosterone level after 
brachytherapy,  with a significant difference in the tes-
tosterone recovery rate at 3 months after brachytherapy.  
However,  there was no significant difference in testos-
terone recovery at 12 months between the GnRH antag-
onist and agonists.  The testosterone recovery rate was 
significantly associated with older age and higher BMI.  
We did not observe superiority of the GnRH antagonist 
over the two agonists in terms of testosterone recovery.  
Long-term follow-up data are needed to determine the 
effects of testosterone recovery on the QOL of prostate 
cancer patients treated with brachytherapy,  according 
to the type of GnRH analogue.
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